モデルナは、mRNA医薬品分野における革新的リーダーです。mRNA技術の進展を通して、モデルナは医薬品の製造方法を根本から変え、疾患の治療と予防へのアプローチを変革し続けています。モデルナは10年以上にわたって科学、技術、健康分野の研究に取り組んでお ...

Influenza hemagglutinin subunit vaccines are more effective and offer better cross protection against various influenza virus ...

RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...

Influenza hemagglutinin subunit vaccines are more effective and offer better cross protection against various influenza virus ...

Moderna said on Monday its experimental influenza vaccine showed superior efficacy compared with a licensed standard-dose ...

Moderna this week announced positive data from a phase 3 trial of its messenger RNA vaccine against seasonal influenza, which ...

Moderna has reported positive phase 3 results for its seasonal flu vaccine, mRNA-1010, which outperformed a standard-dose ...

Newborns are at risk for serious complications from influenza infections but are not eligible for vaccination until they are ...

The virus has not yet evolved to spread efficiently between people. Excellent vaccine technology exists, but the government ...

In parallel, Guyana began weekly reporting of surveillance data to the Pan American Health Organization (PAHO)/World Health Organization (WHO) via FluNet and ...

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

mRNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and older ...